Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Vertex Pharmaceuticals Option Volume And Open ... a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting ...

Vertex Pharmaceuticals (NASDAQ ... Vertex's gene therapy programs, particularly in sickle cell disease and beta-thalassemia, offer another avenue for growth. The progress of CASGEVY will be ...

On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza ...

Vertex Pharmaceuticals (NASDAQ ... signed a reimbursement agreement with NHS England for Casgevy in treating sickle cell disease. Vertex and NHS England previously reached a deal to make the ...

This approval is tremendously important for Vertex Pharmaceuticals ... agreement with NHS England for Casgevy in treating sickle cell disease. Vertex and NHS England previously reached a deal ...

Shares of Vertex Pharmaceuticals (NASDAQ ... for the treatment of sickle cell disease and beta-thalassemia. Casgevy is a one-and-done treatment that Vertex is marketing and developing in ...